Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Euphorbia ebracteolata Hayata is a perennial herb in the Euphorbiaceae family, traditionally used in Chinese medicine (where its dried root is called "langdu") and distributed across China, Korea, and Japan. It has been used to treat edema, skin ulcers, abdominal distension, cough, asthma, tuberculosis swelling and other diseases. The plant contains various bioactive compounds including terpenoids (notably diterpenes such as ingenanes and rosane diterpenoids), acetophenones (such as ECB/2,4-dihydroxy-6-methoxy-3-methylacetophenone), flavonoids, baccatin derivatives and others. Extracts and isolated compounds from E. ebracteolata have demonstrated pharmacological activities such as anticancer (including anti-melanoma activity via inhibition of angiogenesis), anti-inflammatory (notably through suppression of NF-κB activation by compounds like ebractenoid F), antiviral, antimicrobial effects and antidiabetic potential attributed to antioxidant properties. Some constituents also show cytotoxicity against cancer cell lines; however the plant is reported to have toxicity concerns[1][4][7][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on euphorbia ebracteolata hayata.